Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors

被引：0
作者：
Tenaillon, Anne [1 ]
Orbach, Daniel [1 ]
机构：
[1] Inst Curie, Ctr Integre Soins & Rech Oncol Enfant Adolescent &, 26 rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 04期
关键词：
Inflammatory myofibroblastic tumor; Targeted therapy; ALK-positive; Crizotinib; Children;
D O I：
10.1016/j.bulcan.2022.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：248 / 249
页数：2
相关论文
共 50 条
  • [31] Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with Brain Metastases
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S377
  • [32] Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC
    Zhang, Yi-chen
    Zhou, Qing
    Wu, Yi-Long
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1693 - 1701
  • [33] Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
    Nagumo, Yoshiyuki
    Maejima, Aiko
    Toyoshima, Yuta
    Komiyama, Motokiyo
    Yonemori, Kan
    Yoshida, Akihiko
    Fujimoto, Hiroyuki
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2018, 48 : 1 - 4
  • [34] A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib
    Weifeng Liu
    Qianqian Duan
    Lihua Gong
    Yongkun Yang
    Zhen Huang
    Hao Guo
    Xiaohui Niu
    Investigational New Drugs, 2021, 39 : 278 - 282
  • [35] A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib
    Liu, Weifeng
    Duan, Qianqian
    Gong, Lihua
    Yang, Yongkun
    Huang, Zhen
    Guo, Hao
    Niu, Xiaohui
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 278 - 282
  • [36] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [37] ALK-positive inflammatory myofibroblastic tumor harboring ALK gene rearrangement, occurring after allogeneic stem cell transplant in an adult male
    Vroobel, Katherine
    Judson, Ian
    Dainton, Melissa
    McCormick, Alison
    Fisher, Cyril
    Thway, Khin
    PATHOLOGY RESEARCH AND PRACTICE, 2016, 212 (08) : 743 - 746
  • [38] Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S412
  • [39] Successful Desensitization of Two Patients with ALK-Positive Lung Cancer and Hypersensitivity to Crizotinib
    Awad, Mark M.
    Lax, Timothy P.
    Slawski, Benjamin R.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1726 - 1728
  • [40] Crizotinib Versus Chemotherapy On ALK-positive NSCLC: A Systematic Review of Efficacy and Safety
    Wang, Mingxia
    Wang, Guanqi
    Ma, Haiyan
    Shan, Baoen
    CURRENT CANCER DRUG TARGETS, 2019, 19 (01) : 41 - 49
12345